Tumor News and Research

RSS

Study shows hsa-miR-146a overexpressed in most metastatic tumors

In order to kill, bladder cancer must metastasize, most commonly to the lung - what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University of Colorado Cancer Center at the AACR Annual Meeting 2013 shows that one big difference is a little molecule known as hsa-miR-146a.

11 Apr 2013

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.

11 Apr 2013

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Late stage thyroid cancer patients with aggressive disease may benefit from a genetic test, but experts caution that use of this test in early stage patients is inappropriate because it is unlikely to lead to better outcomes.

11 Apr 2013

Study: microRNA is designed to stop proliferation of prostate cancer cells

The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.

10 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

BRAF genetic mutation increases mortality among patients with papillary thyroid cancer

Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.

10 Apr 2013

Six2 homeoprotein causes breast cancer progression, say researchers

In results presented at the AACR Annual Meeting 2013, researchers from the University of Colorado Cancer Center show that the Six2 homeoprotein, while not involved in primary tumor growth, allows cells to detach from substrate and survive their transition through the bloodstream to faraway sites of metastasis.

10 Apr 2013

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors.

10 Apr 2013

New device that detects breast cancer metastasis is extending its market reach

A device co-developed by a University of Houston (UH) physicist to detect the spread of breast cancer and allow physicians to better plan intervention is extending its market reach, bringing it another step closer to clinical trials in the U.S.

10 Apr 2013

CYP1B1 protein prevents head and neck cancers, say researchers

Head and neck cancers typically begin in squamous cells that line moist surfaces inside the mouth, nose and throat. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer in the United States, and it is sometimes preceded by the appearance of changes inside the oral cavity called precancerous lesions.

10 Apr 2013

New study shows combination therapy is effective in treating sarcoma tumors

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors.

10 Apr 2013

Tumors with excess copies of MYCN highly sensitive to BET bromodomain inhibitors, researchers find

An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists will report at the annual meeting of the American Association for Cancer Research in Washington, April 6-10.

10 Apr 2013

First combination treatment of microwave ablation, radiotherapy performed on 52-year-old patient

Dr. Hudayi Korkusuz, a radiologist at the Department of Nuclear Medicine, has conducted the first combination treatment of microwave ablation and radiotherapy.

10 Apr 2013

AACR recognizes UT MD Anderson professor for contributions to cancer research

Guillermina "Gigi" Lozano, Ph.D., chair and professor in the Department of Genetics at The University of Texas MD Anderson Cancer Center, is the recipient of the 16th annual Women in Cancer Research Charlotte Friend Memorial Lectureship awarded by The American Association for Cancer Research, recognizing her contributions to the field of cancer research and the advancement of women in science.

10 Apr 2013

New study shows some women don't stick to recommended treatment for breast cancer

One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.

10 Apr 2013

Researchers evaluate Pexa-Vec to slow progression of liver cancer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

10 Apr 2013

MD Anderson scientists demonstrate new way to restore tumor suppression

Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.

10 Apr 2013

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

Elekta's Versa HD system accelerates radiation delivery to new levels

Featuring a revolutionary combination of speed and accuracy, Elekta's new Versa HD system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels.

From Elekta 10 Apr 2013

Tumor News and Research

Study shows hsa-miR-146a overexpressed in most metastatic tumors

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Study: microRNA is designed to stop proliferation of prostate cancer cells

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

BRAF genetic mutation increases mortality among patients with papillary thyroid cancer

Six2 homeoprotein causes breast cancer progression, say researchers

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

New device that detects breast cancer metastasis is extending its market reach

CYP1B1 protein prevents head and neck cancers, say researchers

New study shows combination therapy is effective in treating sarcoma tumors

Tumors with excess copies of MYCN highly sensitive to BET bromodomain inhibitors, researchers find

First combination treatment of microwave ablation, radiotherapy performed on 52-year-old patient

AACR recognizes UT MD Anderson professor for contributions to cancer research

New study shows some women don't stick to recommended treatment for breast cancer

Researchers evaluate Pexa-Vec to slow progression of liver cancer

MD Anderson scientists demonstrate new way to restore tumor suppression

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Elekta's Versa HD system accelerates radiation delivery to new levels

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News